Phase I Study of Intermittent High Dose Lapatinib Alternating With Capecitabine for HER2-positive Breast Cancer Patients With Central Nervous System Metastases
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-3502
Full Text
Open PDFAbstract
Available in full text
Date
April 15, 2019
Authors
Publisher
American Association for Cancer Research (AACR)